REGENXBIO completes RGX-202 dosing in confirmatory study
REGENXBIO (NASDAQ:RGNX) said it has completed dosing in the confirmatory study of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy, marking completion of its registrational development program.











-640x360.webp&w=3840&q=75)










